Data / Form D filings / Apexigen, Inc.
Apexigen, Inc.: Form D filing
Apexigen, Inc., a biotechnology company in San Carlos, CA, filed a Form D with the SEC in 2023. The latest, on February 14, 2023, reports $5.6 million sold of a $5.6 million offering to 13 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 75 SHOREWAY ROAD, SUITE C, San Carlos, CA, 94070
- Phone
- (650) 931-6236
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2020
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1814140
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Feb 14, 2023 | New notice | $5,587,982 | $5,587,982 | 13 | Jan 30, 2023 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Gordon Ringold | Director | |
| Scott Smith | Director | |
| Herb Cross | Director | |
| Francis Sarena | Executive Officer | |
| Jakob Dupont | Director | |
| Xiaodong Yang | Executive Officer, Director | |
| Amy Wong | Executive Officer | |
| Meenu Karson | Director | |
| Frank Hsu | Executive Officer | |
| Samuel Wertheimer | Director | |
| William Duke, Jr. | Executive Officer | |
| Dan Zabrowski | Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Feb 13, 2023 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Apexigen, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.